Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral

IF 1.5 4区 生物学 Q4 MYCOLOGY Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI:10.1016/j.riam.2021.04.002
Begoña Monge-Maillo, Rogelio López-Vélez
{"title":"Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral","authors":"Begoña Monge-Maillo,&nbsp;Rogelio López-Vélez","doi":"10.1016/j.riam.2021.04.002","DOIUrl":null,"url":null,"abstract":"<div><p>A review on the current evidence of the efficacy and security of liposomal amphotericin<!--> <!-->B (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10<!--> <!-->mg/kg has shown effectiveness in the treatment of VL due to <em>Leishmania donovani</em>. In contrast, higher doses of L-AmB (up to 30<!--> <!-->mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by <em>Leishmania infantum</em> acquired in the Americas and Europe the usual dose of L-AmB is 20-21<!--> <!-->mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60<!--> <!-->mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Iberoamericana De Micologia","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130140621000267","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

A review on the current evidence of the efficacy and security of liposomal amphotericin B (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10 mg/kg has shown effectiveness in the treatment of VL due to Leishmania donovani. In contrast, higher doses of L-AmB (up to 30 mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by Leishmania infantum acquired in the Americas and Europe the usual dose of L-AmB is 20-21 mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60 mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脂质体两性霉素B治疗内脏利什曼病
对两性霉素脂质体B (L-AmB)治疗内脏利什曼病(VL)的有效性和安全性的现有证据进行了综述。在印度次大陆,单次剂量10mg /kg已显示出治疗多诺瓦利什曼原虫引起的VL的有效性。相比之下,在非洲需要更高剂量的L-AmB(高达30毫克/公斤)来治疗相同病因的VL。在美洲和欧洲获得的婴儿利什曼原虫治疗VL时,L-AmB的通常剂量为20- 21mg /kg。在合并感染艾滋病毒的患者中,所需剂量通常较高,可达60毫克/公斤,如果在治疗后以预防性方案给予,则可减少VL复发。L-AmB已显示出与其他抗寄生虫药物的协同作用,特别是在印度次大陆与paromomycin的协同作用以及在东非与合并感染艾滋病毒的患者与miltefosin的协同作用。由于其有效性和安全性,L-AmB是VL的首选治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
17
审稿时长
81 days
期刊介绍: Revista Iberoamericana de Micología (Ibero-American Journal of Mycology) is the official journal of the Asociación Española de Micología, Asociación Venezolana de Micología and Asociación Argentina de Micología (The Spanish, Venezuelan, and Argentinian Mycology Associations). The Journal gives priority to publishing articles on studies associated with fungi and their pathogenic action on humans and animals, as well as any scientific studies on any aspect of mycology. The Journal also publishes, in Spanish and in English, original articles, reviews, mycology forums, editorials, special articles, notes, and letters to the editor, that have previously gone through a scientific peer review process.
期刊最新文献
Clinical response to prednisone in a severe case of infant-juvenile paracoccidioidomycosis Fungemia due to opportunistic fungi in patients with cancer Azole resistance in a clinical isolate of Aspergillus fumigatus from Chile Experimental study of specific and nonspecific blood culture bottles for the diagnosis of candidemia Pneumocystis carinii infection drives upregulation of Fn1 expression that causes pulmonary fibrosis with an inflammatory response
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1